- Home
- FCT vs ADCT Comparison
FCT vs ADCT Comparison
Compare FCT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCT
- ADCT
- Stock Information
- Founded
- FCT 2004
- ADCT 2011
- Country
- FCT United States
- ADCT Switzerland
- Employees
- FCT N/A
- ADCT N/A
- Industry
- FCT Finance Companies
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- FCT Finance
- ADCT Health Care
- Exchange
- FCT Nasdaq
- ADCT Nasdaq
- Market Cap
- FCT 255.2M
- ADCT 241.0M
- IPO Year
- FCT N/A
- ADCT 2020
- Fundamental
- Price
- FCT $10.21
- ADCT $3.28
- Analyst Decision
- FCT
- ADCT Strong Buy
- Analyst Count
- FCT 0
- ADCT 6
- Target Price
- FCT N/A
- ADCT $7.80
- AVG Volume (30 Days)
- FCT 106.8K
- ADCT 733.2K
- Earning Date
- FCT 01-01-0001
- ADCT 08-05-2025
- Dividend Yield
- FCT 11.29%
- ADCT N/A
- EPS Growth
- FCT N/A
- ADCT N/A
- EPS
- FCT N/A
- ADCT N/A
- Revenue
- FCT N/A
- ADCT $75,817,000.00
- Revenue This Year
- FCT N/A
- ADCT $11.75
- Revenue Next Year
- FCT N/A
- ADCT $10.29
- P/E Ratio
- FCT N/A
- ADCT N/A
- Revenue Growth
- FCT N/A
- ADCT 10.49
- 52 Week Low
- FCT $9.45
- ADCT $1.05
- 52 Week High
- FCT $10.42
- ADCT $3.98
- Technical
- Relative Strength Index (RSI)
- FCT 64.85
- ADCT 57.96
- Support Level
- FCT $10.16
- ADCT $2.98
- Resistance Level
- FCT $10.22
- ADCT $3.19
- Average True Range (ATR)
- FCT 0.06
- ADCT 0.22
- MACD
- FCT 0.00
- ADCT 0.01
- Stochastic Oscillator
- FCT 81.82
- ADCT 84.63
About FCT First Trust Senior Floating Rate Income Fund II of Beneficial Interest
First Trust Senior Floating Rate Income Fund II is the United States based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, the fund attempts to preserve capital. The fund seeks to achieve the objectives by investing in a portfolio of senior floating-rate loan interests. Its portfolio of investments consists of aerospace and defense, agricultural products, broadcasting, cable and satellite, electric utilities and other sectors.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).